Zhejiang Jiuzhou Pharm Co Ltd (603456) - Net Assets
Based on the latest financial reports, Zhejiang Jiuzhou Pharm Co Ltd (603456) has net assets worth CN¥8.95 Billion CNY (≈ $1.31 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.59 Billion ≈ $1.55 Billion USD) and total liabilities (CN¥1.64 Billion ≈ $239.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Zhejiang Jiuzhou Pharm Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.95 Billion |
| % of Total Assets | 84.56% |
| Annual Growth Rate | 25.89% |
| 5-Year Change | 92.05% |
| 10-Year Change | 242.47% |
| Growth Volatility | 29.29 |
Zhejiang Jiuzhou Pharm Co Ltd - Net Assets Trend (2008–2025)
This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. See Zhejiang Jiuzhou Pharm Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Jiuzhou Pharm Co Ltd (2008–2025)
The table below shows the annual net assets of Zhejiang Jiuzhou Pharm Co Ltd from 2008 to 2025. For live valuation and market cap data, see how much is Zhejiang Jiuzhou Pharm Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.79 Billion ≈ $1.29 Billion |
+2.10% |
| 2024-12-31 | CN¥8.61 Billion ≈ $1.26 Billion |
+0.90% |
| 2023-12-31 | CN¥8.53 Billion ≈ $1.25 Billion |
+58.86% |
| 2022-12-31 | CN¥5.37 Billion ≈ $786.02 Million |
+17.35% |
| 2021-12-31 | CN¥4.58 Billion ≈ $669.78 Million |
+48.31% |
| 2020-12-31 | CN¥3.09 Billion ≈ $451.60 Million |
+7.97% |
| 2019-12-31 | CN¥2.86 Billion ≈ $418.27 Million |
+2.89% |
| 2018-12-31 | CN¥2.78 Billion ≈ $406.52 Million |
+3.63% |
| 2017-12-31 | CN¥2.68 Billion ≈ $392.28 Million |
+4.44% |
| 2016-12-31 | CN¥2.57 Billion ≈ $375.60 Million |
+2.03% |
| 2015-12-31 | CN¥2.52 Billion ≈ $368.13 Million |
+58.90% |
| 2014-12-31 | CN¥1.58 Billion ≈ $231.68 Million |
+114.90% |
| 2013-12-31 | CN¥736.75 Million ≈ $107.81 Million |
+23.39% |
| 2012-12-31 | CN¥597.08 Million ≈ $87.37 Million |
+29.65% |
| 2011-12-31 | CN¥460.54 Million ≈ $67.39 Million |
+33.90% |
| 2010-12-31 | CN¥343.94 Million ≈ $50.33 Million |
+39.89% |
| 2009-12-31 | CN¥245.87 Million ≈ $35.98 Million |
+40.17% |
| 2008-12-31 | CN¥175.41 Million ≈ $25.67 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Jiuzhou Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5588.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.32 Billion | 38.01% |
| Other Components | CN¥5.41 Billion | 61.99% |
| Total Equity | CN¥8.72 Billion | 100.00% |
Zhejiang Jiuzhou Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Jiuzhou Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
$1.71 Billion |
|
Beijer Alma AB (publ)
ST:BEIA-B
|
$1.71 Billion |
|
Agios Pharm
NASDAQ:AGIO
|
$1.71 Billion |
|
Kfin Technologies Limited
NSE:KFINTECH
|
$1.71 Billion |
|
Tien Phong Commercial Joint Stock Bank
VN:TPB
|
$1.71 Billion |
|
Greif Bros Corporation
NYSE:GEF
|
$1.71 Billion |
|
Wuxi Shangji Automation Co Ltd
SHG:603185
|
$1.71 Billion |
|
Bukit Asam Tbk PT
JK:PTBA
|
$1.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Jiuzhou Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,536,673,816 to 8,724,119,573, a change of 187,445,757 (2.2%).
- Net income of 730,073,370 contributed positively to equity growth.
- Dividend payments of 450,406,267 reduced retained earnings.
- Other factors decreased equity by 92,221,347.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥730.07 Million | +8.37% |
| Dividends Paid | CN¥450.41 Million | -5.16% |
| Other Changes | CN¥-92.22 Million | -1.06% |
| Total Change | CN¥- | 2.20% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Jiuzhou Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.29x to 1.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.65 | CN¥13.12 | x |
| 2009-12-31 | CN¥0.91 | CN¥13.12 | x |
| 2010-12-31 | CN¥1.27 | CN¥13.12 | x |
| 2011-12-31 | CN¥0.81 | CN¥13.12 | x |
| 2012-12-31 | CN¥1.05 | CN¥13.12 | x |
| 2013-12-31 | CN¥1.31 | CN¥13.12 | x |
| 2014-12-31 | CN¥2.60 | CN¥13.12 | x |
| 2015-12-31 | CN¥3.14 | CN¥13.12 | x |
| 2016-12-31 | CN¥3.19 | CN¥13.12 | x |
| 2017-12-31 | CN¥3.26 | CN¥13.12 | x |
| 2018-12-31 | CN¥3.53 | CN¥13.12 | x |
| 2019-12-31 | CN¥3.55 | CN¥13.12 | x |
| 2020-12-31 | CN¥3.84 | CN¥13.12 | x |
| 2021-12-31 | CN¥5.49 | CN¥13.12 | x |
| 2022-12-31 | CN¥6.38 | CN¥13.12 | x |
| 2023-12-31 | CN¥9.50 | CN¥13.12 | x |
| 2024-12-31 | CN¥9.51 | CN¥13.12 | x |
| 2025-12-31 | CN¥9.81 | CN¥13.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Jiuzhou Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.37%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.25%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.22x
- Recent ROE (8.37%) is below the historical average (14.83%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 24.06% | 7.01% | 1.01x | 3.41x | CN¥24.21 Million |
| 2009 | 27.76% | 10.30% | 1.03x | 2.62x | CN¥43.00 Million |
| 2010 | 32.36% | 13.18% | 0.97x | 2.52x | CN¥75.91 Million |
| 2011 | 25.63% | 12.52% | 0.84x | 2.44x | CN¥71.37 Million |
| 2012 | 22.99% | 11.92% | 0.85x | 2.27x | CN¥77.00 Million |
| 2013 | 22.69% | 12.69% | 0.84x | 2.12x | CN¥92.98 Million |
| 2014 | 8.43% | 10.36% | 0.58x | 1.40x | CN¥-24.81 Million |
| 2015 | 7.95% | 13.85% | 0.43x | 1.33x | CN¥-51.50 Million |
| 2016 | 4.35% | 6.74% | 0.55x | 1.17x | CN¥-144.53 Million |
| 2017 | 5.52% | 8.59% | 0.55x | 1.17x | CN¥-119.91 Million |
| 2018 | 5.67% | 8.44% | 0.56x | 1.19x | CN¥-120.21 Million |
| 2019 | 8.33% | 11.79% | 0.43x | 1.64x | CN¥-47.67 Million |
| 2020 | 12.34% | 14.38% | 0.53x | 1.62x | CN¥72.26 Million |
| 2021 | 13.85% | 15.60% | 0.58x | 1.54x | CN¥176.19 Million |
| 2022 | 17.39% | 16.92% | 0.69x | 1.49x | CN¥391.51 Million |
| 2023 | 12.21% | 18.71% | 0.51x | 1.28x | CN¥187.14 Million |
| 2024 | 7.10% | 11.74% | 0.46x | 1.30x | CN¥-247.57 Million |
| 2025 | 8.37% | 13.25% | 0.52x | 1.22x | CN¥-142.34 Million |
Industry Comparison
This section compares Zhejiang Jiuzhou Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Jiuzhou Pharm Co Ltd (603456) | CN¥8.95 Billion | 24.06% | 0.18x | $1.71 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Zhejiang Jiuzhou Pharm Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and … Read more